Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells

Inclusion Criteria

• •1. Written informed consent was obtained to participate in the study and HIPAA authorization for the release of personal health information.
• •2. The subject is willing and able to comply with study procedures based on the judgment of the investigator.
• •3. Age ≥ 18 years at the time of consent.
• •4. Planning to receive a commercial CD19 or BCMA-directed CAR-T therapy or investigational CD30 or solid tumor CAR-T therapy as a single infusion following lymphodepletion
• •5. Agree to provide blood samples as required by the protocol
• •6. Willing and able to provide access to immunization history
• •7. If receiving CAR-T as part of a clinical trial, must meet all eligibility criteria for that trial
• •8. Be willing to attend Immune Reconstitution Clinic Visits at 3, 6, 9, 12 months after CAR T-cell infusion
• •9. Be willing to receive PCV-21 vaccination at 6 months after CAR T-cell infusion.